The implementation of LCD, L35396 “Genetic Testing for Oncology” that would have resulted in Pacific Edge’s (PEB) CMS reimbursement ceasing on 17 July 2023 has been delayed; In the interim, PEB will continue to be reimbursed for its CMS tests (~77% of FY23 operating revenue) which is a clear near-term positive against prior expectations of a significant revenue reduction and business disruption
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.